|
Re: Endocyte Valuation
|
2
|
Zenith Epigenetics
|
Oct 18, 2018 02:54PM
|
|
Re: Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
|
6
|
Resverlogix Corp.
|
Oct 22, 2018 10:28AM
|
|
Re: Resverlogix H2 2018 events
|
5
|
Resverlogix Corp.
|
Oct 24, 2018 01:19PM
|
|
Re: Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
|
4
|
Resverlogix Corp.
|
Oct 26, 2018 01:36PM
|
|
Re: Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
|
2
|
Resverlogix Corp.
|
Oct 28, 2018 08:33AM
|
|
BIO Europe
|
3
|
Zenith Epigenetics
|
Oct 28, 2018 08:34AM
|
|
Re: ESPR results
|
9
|
Resverlogix Corp.
|
Oct 28, 2018 11:28PM
|
|
Re: First xB3 platform technology licensing agreement with Prothena; USD$1M upfront+potential up to USD$33M in payments
|
3
|
BIOASIS TECHNOLOGIES INC
|
Oct 29, 2018 08:40AM
|
|
Roth coverage
|
4
|
Resverlogix Corp.
|
Oct 29, 2018 11:59AM
|
|
The scariest thing for a clinical trial......
|
2
|
Resverlogix Corp.
|
Oct 31, 2018 07:24PM
|
|
Re: Roth research report
|
8
|
Resverlogix Corp.
|
Oct 31, 2018 10:20PM
|
|
Re: Roth research report
|
3
|
Resverlogix Corp.
|
Nov 01, 2018 09:47AM
|
|
Re: The scariest thing for a clinical trial......
|
7
|
Resverlogix Corp.
|
Nov 01, 2018 10:58AM
|
|
Re: Roth research report
|
2
|
Resverlogix Corp.
|
Nov 01, 2018 04:17PM
|
|
Re: RVX buyout projection at $30 US minimum
|
4
|
Resverlogix Corp.
|
Nov 01, 2018 05:33PM
|
|
Re: 3 point MACE vs 5 point MACE
|
6
|
Resverlogix Corp.
|
Nov 02, 2018 10:41AM
|
|
Re: 3 point MACE vs 5 point MACE
|
5
|
Resverlogix Corp.
|
Nov 02, 2018 01:17PM
|
|
Re: 3 point MACE vs 5 point MACE
|
4
|
Resverlogix Corp.
|
Nov 02, 2018 01:23PM
|
|
Re: 3 point MACE vs 5 point MACE
|
3
|
Resverlogix Corp.
|
Nov 02, 2018 01:32PM
|
|
Re: 3 point MACE vs 5 point MACE
|
2
|
Resverlogix Corp.
|
Nov 02, 2018 02:54PM
|
